Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

Zymeworks Inc.

Therini Bio develops immunotherapies for neuroinflammation in diseases driven by vascular dysfunction. It focuses on a clinical-stage pipeline aimed at treating severe neurological and retinal diseases.

Therini Bio

Umoja Biopharma develops integrated platform therapeutics that reprogram the immune system to target cancer cells and generate lasting remissions.

Umoja Biopharma

Li Lab of Computational Cancer Immunology focuses on cancer research, particularly on the computational analysis of immune responses in cancer. The lab has conducted various studies related to T cell receptor repertoires, mitochondrial transfer between cells, and cancer immunotherapy.

Li Lab of Computational Cancer Immunology

Zymeworks develops novel medicines for patients with difficult-to-treat cancers and other serious diseases. Its research is focused on transforming areas of high unmet medical need.

Metric
Company Name	Zymeworks Inc.	Therini Bio	Umoja Biopharma	Li Lab of Computational Cancer Immunology
Symbol	ZYME
MSH ID	COM:ZYMEWORKS	COM:THERINIBIO	COM:UMOJA-BIOPHARMA	ORG:LILAB-UTSW
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology	Biotechnology
Country	CA	US	US	US
Stage	Post-IPO Equity
Employee Count	275
Website	zymeworks.com	therinibio.com	umoja-biopharma.com	lilab-utsw.org
LinkedIn		therinibio
Founders

Metric
Market Cap	653.31M
Enterprise Value
Monthly Web Traffic	5.39K	6.83K
Web Traffic Growth	0.26	-0.19
Valuation
Raised Capital	37.89M

Metric
Revenue	76.01M
Revenue (LTM)
Revenue (NTM)
Gross Profit	76.01M
EBITDA	-119.52M
Operating Income	-138.05M
Net Income	-118.67M
EPS	-1.72
Diluted EPS	-1.72
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-0.49
Operating Profit Margin	-1.82
EBITDA Margin	-1.57
Net Profit Margin	-1.56
Return on Equity	-0.26
Return on Assets	-0.20
Return on Capital Employed	-0.26

COM:ZYMEWORKS

Zymeworks

Last Close

13.68

22/11 21:00

Market Cap

653.31M

Beta: -

Volume Today

511.98K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	3.79
P/B Ratio	1.83
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	19.07
EV Multiple	-4.95

Metric
Days Sales Outstanding	53.20
Days Payables Outstanding
Days Inventory Outstanding	0.00
Operating Cycle	279.38
Cash Conversion Cycle	272.42
Asset Turnover	0.13

Metric
Operating Cash Flow	-118.30M
Free Cash Flow	-122.38M
Cash Flow to Debt	-0.01
Operating Cash Flow/Sales	-1.44
Free Cash Flow Yield	0.25

Metric
Cash & Equivalents	157.56M
Accounts Receivable	13.92M
Inventory
Goodwill	12.02M
Debt to Capitalization	0.98
Debt to Assets	0.05
Current Ratio	5.14
Quick Ratio	7.06

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.02
R&D to Revenue	0.34
SG&A to Revenue	0.19